Our CEO, Dr Tim Oldham was recently interviewed by Stuart Roberts of Pitt Street Research about AdAlta’s growth strategy and upcoming Phase 1 clinical trials of lead candidate, AD-214 which are due to commence in mid-2020.
In the interview, Dr Oldham speaks about how AdAlta is “the first company to use the CXCR4 axis to attack fibrosis” and how AdAlta is targeting a larger market than IPF with multiple disease indications for AD-214.
To view the interview, click here.
